Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (previously presented) A method of treating depression in a patient comprising administering a therapeutic amount of a drug condensation aerosol to the patient by inhalation,

wherein the drug is selected from the group consisting of bupropion, nefazodone, perphenazine, trazodone, trimipramine, venlafaxine, tranylcypromine, citalopram, fluoxetine, fluvoxamine, mirtazepine, paroxetine, sertraline, amoxapine, clomipramine, doxepin, imipramine, maprotiline, nortriptylene, valproic acid and protriptylene, and

wherein the condensation aerosol is formed by heating a thin layer containing the drug, on a solid support, to produce a vapor of the drug, and condensing the vapor to form a condensation aerosol characterized by less than 10% drug degradation products by weight, and an MMAD of less than 5 microns.

2. (previously presented) The method according to claim 1, wherein the condensation aerosol is characterized by an MMAD of less than 3 microns.

3. (previously presented) The method according to claim 1, wherein peak plasma drug concentration is reached in less than 0.1 hours.

4. (cancelled)

5. (previously presented) The method according to claim 1, wherein the condensation aerosol is formed at a rate greater than 0.5 mg/second.

6. (original) The method according to claim 1, wherein at least 50% by weight of the condensation aerosol is amorphous in form.

7.-10. (cancelled)

11. (previously presented) The method according to claim 1, wherein the therapeutic amount of a drug condensation aerosol comprises between 20 mg and 150 mg of bupropion delivered in a single inspiration.

12. (previously presented) The method according to claim 1, wherein the therapeutic amount of a drug condensation aerosol comprises between 20 mg and 200 mg of nefazodone delivered in a single inspiration.

13. (previously presented) The method according to claim 1, wherein the therapeutic amount of a drug condensation aerosol comprises between 0.5 mg and 3 mg of perphenazine delivered in a single inspiration.

14. (previously presented) The method according to claim 1, wherein the therapeutic amount of a drug condensation comprises between 20 mg and 100 mg of trazodone delivered in a single inspiration.

15. (previously presented) The method according to claim 1, wherein the therapeutic amount of a drug condensation aerosol comprises between 20 mg and 150 mg of trimipramine delivered in a single inspiration.

16. (previously presented) The method according to claim 1, wherein the therapeutic amount of a drug condensation aerosol comprises between 20 mg and 100 mg of venlafaxine delivered in a single inspiration.

17. (previously presented) The method according to claim 1, wherein the therapeutic amount of a drug condensation aerosol comprises between 7.5 mg and 20 mg of tranylcypromine delivered in a single inspiration.

18. (previously presented) The method according to claim 1, wherein the therapeutic amount of a drug condensation aerosol comprises between 10 mg and 30 mg of citalopram delivered in a single inspiration.

19. (previously presented) The method according to claim 1, wherein the therapeutic amount of a drug condensation aerosol comprises between 10 mg and 30 mg of fluoxetine delivered in a single inspiration.

20. (previously presented) The method according to claim 1, wherein the therapeutic amount of a drug condensation aerosol comprises between 20 mg and 50 mg of fluvoxamine delivered in a single inspiration.

21. (previously presented) The method according to claim 1, wherein the therapeutic amount of a drug condensation aerosol comprises between 7.5 mg and 20 mg of mirtazepine delivered in a single inspiration.

22. (previously presented) The method according to claim 1, wherein the therapeutic amount of a drug condensation aerosol comprises between 5 mg and 30 mg of paroxetine delivered in a single inspiration.

23. (previously presented) The method according to claim 1, wherein the therapeutic amount of a drug condensation aerosol comprises between 15 mg and 50 mg of sertraline delivered in a single inspiration.

24. (previously presented) The method according to claim 1, wherein the therapeutic amount of a drug condensation aerosol comprises between 20 mg and 150 mg of amoxapine delivered in a single inspiration.

25. (previously presented) The method according to claim 1, wherein the therapeutic amount of a drug condensation aerosol comprises between 20 mg and 100 mg of clomipramine delivered in a single inspiration.

26. (previously presented) The method according to claim 1, wherein the therapeutic amount of a drug condensation aerosol comprises between 20 mg and 100 mg of doxepin delivered in a single inspiration.

27. (previously presented) The method according to claim 1, wherein the therapeutic amount of a drug condensation aerosol comprises between 20 mg and 100 mg of imipramine delivered in a single inspiration.

28. (previously presented) The method according to claim 1, wherein the therapeutic amount of a drug condensation aerosol comprises between 20 mg and 50 mg of maprotiline delivered in a single inspiration.

29. (previously presented) The method according to claim 1, wherein the therapeutic amount of a drug condensation aerosol comprises between 20 mg and 50 mg of nortriptylene delivered in a single inspiration.

30. (previously presented) The method according to claim 1, wherein the therapeutic amount of a drug condensation aerosol comprises between 100 mg and 400 mg of valproic acid delivered in a single inspiration.

31. (previously presented) The method according to claim 1, wherein the therapeutic amount of a drug condensation aerosol comprises between 7.5 mg and 20 mg of protriptylene delivered in a single inspiration.

32. (currently amended) A method of administering a drug condensation aerosol to a patient comprising administering the drug condensation aerosol to the patient by inhalation,

wherein the drug is selected from the group consisting of bupropion, nefazodone, perphenazine, trazodone, trimipramine, venlafaxine, tranylcypromine, citalopram, fluoxetine, fluvoxamine, mirtazepine, paroxetine, sertraline, amoxapine, clomipramine, doxepin, imipramine, maprotiline, nortriptylene, valproic acid and protriptylene, and

wherein the drug condensation aerosol is formed by heating a thin layer containing the drug, on a solid support, to produce a vapor of the drug, and condensing the vapor to form a condensation aerosol characterized by less than 10% drug degradation products by weight, and an MMAD of less than 5 microns.

33. (cancelled)

34. (previously presented) A kit for delivering a drug condensation aerosol comprising:

a. a thin layer containing the drug, on a solid support, wherein the drug is selected from the group consisting of bupropion, nefazodone, perphenazine, trazodone, trimipramine, venlafaxine, tranylcypromine, citalopram, fluoxetine, fluvoxamine, mirtazepine, paroxetine, sertraline, amoxapine, clomipramine, doxepin, imipramine, maprotiline, nortriptylene, valproic acid and protriptylene, and

b. a device for providing the condensation aerosol, wherein the condensation aerosol is formed by heating the thin layer to produce a vapor of the drug, and condensing the vapor to form a condensation aerosol characterized by less than 10% drug degradation products by weight, and an MMAD of less than 5 microns.

35. (cancelled)

36. (previously presented) The kit according to claim 34, wherein the device comprises:

a. a flow through enclosure containing the solid support,

b. a power source that can be activated to heat the solid support, and

c. at least one portal through which air can be drawn by inhalation,

wherein activation of the power source is effective to produce a vapor of the drug, and drawing air through the enclosure is effective to condense the vapor to form the condensation aerosol.

37. (previously presented) The kit according to claim 36, wherein the heat for heating the solid support is generated by an exothermic chemical reaction.

38. (previously presented) The kit according to claim 37, wherein the exothermic chemical reaction is oxidation of combustible materials.

39. (previously presented) The kit according to claim 36, wherein the heat for heating the solid support is generated by passage of current through an electrical resistance element.

40. (previously presented) The kit according to Claim 36, wherein said solid support has a surface area dimensioned to accommodate a therapeutic dose of the drug.

41. (currently amended) The kit according to claim 34, wherein peak plasma drug concentration the drug is reached in less than 0.1 hours.

42. (previously presented) The kit according to claim 34, further including instructions for use.

43. (previously presented) The method according to claim 1, wherein the condensation aerosol is characterized by an MMAD of 0.2 to 5 microns.

44. (previously presented) The method according to claim 2, wherein the condensation aerosol is characterized by an MMAD of 0.2 to 3 microns.

45.-48. (cancelled)

49. (previously presented) The method according to claim 32, wherein the drug is bupropion.

50. (previously presented) The method according to claim 32, wherein the drug is nefazodone.

51. (previously presented) The method according to claim 32, wherein the drug is perphenazine.

52. (previously presented) The method according to claim 32, wherein the drug is trazodone.

53. (previously presented) The method according to claim 32, wherein the drug is trimipramine.

54. (previously presented) The method according to claim 32, wherein the drug is venlafaxine.

55. (previously presented) The method according to claim 32, wherein the drug is tranylcypromine.

56. (previously presented) The method according to claim 32, wherein the drug is citalopram.

57. (previously presented) The method according to claim 32, wherein the drug is fluoxetine.

58. (previously presented) The method according to claim 32, wherein the drug is fluvoxamine.

59. (previously presented) The method according to claim 32, wherein the drug is mirtazepine.

60. (previously presented) The method according to claim 32, wherein the drug is paroxetine.

61. (previously presented) The method according to claim 32, wherein the drug is sertraline.

62. (previously presented) The method according to claim 32, wherein the drug is amoxapine.

63. (previously presented) The method according to claim 32, wherein the drug is clomipramine.

64. (previously presented) The method according to claim 32, wherein the drug is doxepin.

65. (previously presented) The method according to claim 32, wherein the drug is imipramine.

66. (previously presented) The method according to claim 32, wherein the drug is maprotiline.

67. (previously presented) The method according to claim 32, wherein the drug is nortriptylene.

68. (previously presented) The method according to claim 32, wherein the drug is valproic acid.

69. (previously presented) The method according to claim 32, wherein the drug is protriptylene.

70. (previously presented) The kit according to claim 34, wherein the condensation aerosol is characterized by an MMAD of less than 3 microns.

71. (previously presented) The kit according to claim 34, wherein the condensation aerosol is characterized by an MMAD of 0.2 to 5 microns.

72. (previously presented) The kit according to claim 70, wherein the condensation aerosol is characterized by an MMAD of 0.2 to 3 microns.

73.-76. (cancelled)

77. (previously presented) The kit according to claim 34, wherein the drug is bupropion.

78. (previously presented) The kit according to claim 34, wherein the drug is nefazodone.

79. (previously presented) The kit according to claim 34, wherein the drug is perphenazine.

80. (previously presented) The kit according to claim 34, wherein the drug is trazodone.

81. (previously presented) The kit according to claim 34, wherein the drug is trimipramine.

82. (previously presented) The kit according to claim 34, wherein the drug is venlafaxine.

83. (previously presented) The kit according to claim 34, wherein the drug is tranylcypromine.

84. (previously presented) The kit according to claim 34, wherein the drug is citalopram.

85. (previously presented) The kit according to claim 34, wherein the drug is fluoxetine.

86. (previously presented) The kit according to claim 34, wherein the drug is fluvoxamine.

87. (previously presented) The kit according to claim 34, wherein the drug is mirtazepine.

88. (previously presented) The kit according to claim 34, wherein the drug is paroxetine.

89. (previously presented) The kit according to claim 34, wherein the drug is sertraline.

90. (previously presented) The kit according to claim 34, wherein the drug is amoxapine.

91. (previously presented) The kit according to claim 34, wherein the drug is clomipramine.

92. (previously presented) The kit according to claim 34, wherein the drug is doxepin.

93. (previously presented) The kit according to claim 34, wherein the drug is imipramine.

94. (previously presented) The kit according to claim 34, wherein the drug is maprotiline.

95. (previously presented) The kit according to claim 34, wherein the drug is nortriptylene.

96. (previously presented) The kit according to claim 34, wherein the drug is valproic acid.

97. (previously presented) The kit according to claim 34, wherein the drug is protriptylene.

98. (previously presented) The kit according to claim 36, wherein the solid support has a surface to mass ratio of greater than 1 cm^2 per gram.

99. (previously presented) The kit according to claim 36, wherein the solid support has a surface to volume ratio of greater than 100 per meter.

100. (previously presented) The kit according to claim 36, wherein the solid support is a metal foil.

101. (previously presented) The kit according to claim 100, wherein the metal foil has a thickness of less than 0.25 mm.